Subcutaneous C1-INH regulatory update

FDA accepted for review a BLA from CSL for CSL830 to prevent hereditary angioedema (HAE) attacks. The therapy is a low-volume, subcutaneous complement 1 (C1) esterase inhibitor. CSL markets an IV ver...